×
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Calvo E., Garralda E., Alonso G., Gambardella V., Parkes EE., Thompson J., Latek R., Sikken P., Schmohl M., Harrington KJ.
DOI
10.1016/j.annonc.2023.09.2169
Type
Conference paper
Publication Date
2023
Volume
34
Pages
S626 - S626